Navigation Links
Mesa Labs Reports 6% Increase in First Quarter Revenues

LAKEWOOD, Colo., Aug. 6, 2013 /PRNewswire/ -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (we, us, our, "Mesa" or the "Company") today reported a six percent increase in revenues for the first quarter ended June 30, 2013.

Revenues for the first quarter increased six percent to $11,218,000 as compared to $10,559,000 for the same quarter last year.  Net income for the first quarter decreased 11 percent to $1,860,000 or $0.52 per diluted share of common stock as compared to $2,099,000 or $0.59 per diluted share of common stock for the same quarter last year. 

On a non-GAAP basis, adjusted net income (which excludes the non-cash impact of amortization of intangible assets, net of tax) for the first quarter decreased ten percent to $2,238,0001 or $0.63 per diluted share of common stock as compared to $2,482,000 or $0.70 per diluted share of common stock for the same quarter last year.

"This was a quarter of mixed results for Mesa," said John J. Sullivan, President and Chief Executive Officer.  "Our Instruments Division revenues increased 17 percent and its gross margin as a percentage of revenues improved from 65 percent to 67 percent, compared to the same quarter last year.  Both of these increases were driven primarily by the acquisition of the Bios flow calibrator business in the same quarter last year.  However, we experienced an unusual event in our Biological Indicators ("BI") Division that depressed sales and margins for the quarter.  Revenues decreased five percent and gross margin as a percentage of revenues decreased from 57 percent last year to 53 percent this year.  The declines were due to an initiative to replace three batches of non-conforming product that had been shipped to customers in previous months.  The product in question had longer than expected incubation times, which is used to determine a positive or negative BI test result.  We chose to dedicate a significant portion of our production capacity to replacement product rather than new orders, which lowered revenues for the quarter and increased our cost of goods sold.  However, our customers wound up with high-quality Mesa product and we believe that little or no business will be lost in this process.  We expect to recover the delayed shipments during our second quarter, with gross margins returning to normal levels in the second or third quarter.  We also don't anticipate this being an issue again in the future as we have implemented new spore crop screening procedures to now identify such issues prior to manufacture or shipment.  The overall decline in Mesa's net income for this quarter, as compared to the same quarter in the previous year, was also primarily due to the effects of this product replacement initiative."

"On a positive note, we are excited about the acquisition of the SureTorque line of bottle cap torque testing products that was concluded immediately after the end of our first quarter," continued John Sullivan.  "The SureTorque products are widely used in the pharmaceutical and biotechnology industries for quality control of bottling processes, which complements our existing line of torque testing instruments, that has gained wide acceptance in the food and beverage industries.  With the combination of the two lines of bottle cap torque testing instrumentation, we will be able to offer a wider range of products to a broader set of potential customers.  The SureTorque acquisition illustrates our commitment to growing our business through strategic acquisitions."

1 The non-GAAP measures of adjusted net income and adjusted net income per diluted share are defined to exclude the non-cash impact of amortization of intangible assets, net of tax. A reconciliation between these non-GAAP measures and their GAAP counterparts is set forth in the table below, along with additional information regarding their use.

Financial SummaryStatements of Income(Unaudited)(Amounts in thousands, except per share data)  Three months ended
June 30,20132012Revenues

$ 11,218

$ 10,559Cost of revenues


4,104  Gross profit


6,455Operating expenses


3,236  Operating income


3,219Other expense, net


34  Earnings before income taxes


3,185Income taxes


1,086  Net income

$  1,860

$   2,099Net income per share (basic)

$ 0.55

$ 0.63Net income per share (diluted)


0.59Weighted average common shares outstanding:Basic




3,541 Balance Sheets(Amounts in thousands)June 30,
2013(Unaudited)March 31,
2013Cash and cash equivalents

$   3,589

$   4,006Other current assets


15,449  Total current assets


19,455Property, plant and equipment, net


7,406Other assets


39,058  Total assets

$ 63,842$ 65,919Liabilities

$   9,387

$   13,166Stockholders' equity


52,753  Total liabilities and stockholders' equity

$ 63,842

$ 65,919 Reconciliation of Non-GAAP Measures(Unaudited)(Amounts in thousands, except per share data)Three months ended
June 30,20132012Net income

$ 1,860

$ 2,099Amortization of intangible

  assets, net of tax




383Adjusted net income

$ 2,238

$ 2,482Adjusted net income per share (basic)

$ 0.66

$ 0.74Adjusted net income per share (diluted)


0.70Weighted average common shares outstanding:Basic




3,541The non-GAAP measures of adjusted net income and adjusted net income per share presented in the reconciliation above are defined to exclude the non-cash impact of amortization of intangible assets, net of tax. The tax effect is calculated using the average corporate rate for that period multiplied by the amortization. We believe that excluding these acquisition related expenses provides the ability to understand the benefits of acquisitions based on their cash return.

We provide non-GAAP adjusted net income and non-GAAP adjusted net income per share amounts in order to provide meaningful supplemental information regarding our operational performance. Our management uses non-GAAP measures to evaluate the performance of our business and to compensate employees. This information facilitates management's internal comparisons to our historical operating results as well as to the operating results of our competitors. Since management finds this measure to be useful, we believe that our investors can benefit by evaluating both non-GAAP and GAAP results.

Our management recognizes that items such as amortization of intangible assets can have a material impact on our net income. To gain a complete picture of all effects on our profit and loss from any and all events, management does (and investors should) rely upon the GAAP statements of income. The non-GAAP numbers focus instead upon our core operating business.

Readers are reminded that non-GAAP measures are merely a supplement to, and not a replacement for, or superior to financial measures prepared according to GAAP. They should be evaluated in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

About Mesa Laboratories, Inc.

We pursue a strategy of focusing primarily on quality control products, which are sold into niche markets that are driven by regulatory requirements. We prefer markets that have limited competition where we can establish a commanding presence and achieve high gross margins.  We are organized into two divisions across four physical locations.  Our Instruments Division designs, manufactures and markets quality control instruments and disposable products utilized in connection with the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, semiconductor and petrochemical industries.  Our Biological Indicators Division manufactures and markets biological indicators and distributes chemical indicators used to assess the effectiveness of sterilization processes, including steam, gas, hydrogen peroxide and radiation, in the hospital, dental, medical device and pharmaceutical industries.

Forward Looking Statements

This press release may contain information that constitutes "forward-looking statements." Generally, the words "believe," "expect," "intend," "estimate," "anticipate," "project," "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future — including statements relating to revenue growth and statements expressing general views about future operating results — are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. These risks and uncertainties include, but are not limited to, those described in our Annual Report on Form 10-K for the year ended March 31, 2013, and those described from time to time in our subsequent reports filed with the Securities and Exchange Commission.

SOURCE Mesa Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. China Biologic Reports Financial Results for the Second Quarter and First Half of 2013
2. BioMed Realty Trust Reports Second Quarter 2013 Financial Results
3. Avanir Pharmaceuticals Reports Fiscal 2013 Third Quarter Financial and Business Results
4. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
5. Cumberland Pharmaceuticals Reports Second Quarter Financial Results
6. Isis Reports Financial Results and Highlights for Second Quarter 2013
7. CVS Caremark Reports Record Second Quarter Results
8. BioLineRx Reports Second Quarter 2013 Results
9. Regeneron Reports Second Quarter 2013 Financial and Operating Results
10. Cytos Biotechnology Ltd Reports Second Quarter 2013 Financial Results and Recent Developments
11. Volcano Reports Second Quarter Results; Medical Segment Revenues Increase More Than 13 Percent On A Constant Currency Basis
Post Your Comments:
(Date:5/24/2016)... -- Joe Marziani has joined VMS BioMarketing as senior vice president of sales, announced ... role, Marziani will lead the company,s business development and sales team, exploring new opportunities ... Photo - ... ... ...
(Date:5/24/2016)... 24, 2016 ... , la première endoprothèse à double thérapie ... l,intervention portant sur les membres inférieurs et ... OrbusNeich, entreprise mondiale spécialisée dans la fourniture ... vie, a élargi son portefeuille pour inclure ...
(Date:5/24/2016)... , May 24, 2016 Een ... verbindt, zodat zij collectief patiënten kunnen behandelen, hun kennis ... het idee achter de nieuwe en revolutionaire MDLinking App, ... de Nederlandse vaatchirurg dr. Hans Flu en oncologisch chirurg ... die inmiddels beschikbaar is, wordt op dinsdag 24 mei ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent ... for drugs, biologics, consumer health and global clinical supply services, today announced two ... support the company’s continued investment and strategic growth plans in the Asia Pacific ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... supply chain solutions, today announced the organization has earned its ISO 13485 certification, ... and is compliant with all rules and policies associated with ISO quality standard ...
(Date:5/26/2016)... New York, NY (PRWEB) , ... May 26, ... ... cell researcher, founder of Mehling Orthopedics and chief medical officer of Blue Horizon ... Musculoskeletal Disease and Regeneration. The conference was held during May 5-6, 2016 in ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... to oncology professionals, has added National Cancer Institute-designated University of Virginia (UVA) ... In this new partnership, OncLive’s editorial and marketing teams will publicize and promote ...
(Date:5/26/2016)... ... May 26, 2016 , ... Metcalf & ... over 20 years of experience in leading technology and human resources operations for ... university teaching, Morrow-Fox will be featured on Metcalf’s VoiceAmerica radio show , ...
Breaking Medicine News(10 mins):